Jennison Associates LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Jennison Associates boosted its stake in Thermo Fisher by 10.2% in Q4 to 277,111 shares (about $160.6M), and institutional/hedge fund ownership totals roughly 89.23%.
• Thermo Fisher beat April-quarter expectations with EPS of $5.44 (vs. $5.25) and revenue of $11.01B (+6.2% YoY), and set FY2026 EPS guidance of 24.64–25.12 (analyst consensus ~24.83).
• The company raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield), while insiders have sold about 5,800 shares (~$2.96M) in the last three months and now own ~0.33% of the stock.

Jennison Associates LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 277,111 shares of the medical research company's stock after purchasing an additional 25,644 shares during the period. Jennison Associates LLC owned about 0.07% of Thermo Fisher Scientific worth $160,572,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Howard Capital Management Inc. raised its stake in shares of Thermo Fisher Scientific by 0.5% in the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after purchasing an additional 16 shares during the last quarter. Petros Family Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 3.9% in the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company's stock worth $264,000 after purchasing an additional 17 shares during the last quarter. Salomon & Ludwin LLC raised its stake in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after purchasing an additional 17 shares during the last quarter. Financial Management Network Inc. raised its stake in shares of Thermo Fisher Scientific by 3.7% in the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company's stock worth $248,000 after purchasing an additional 18 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company's stock worth $728,000 after purchasing an additional 18 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $467.38 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a market cap of $173.69 billion, a price-to-earnings ratio of 25.59, a price-to-earnings-growth ratio of 2.07 and a beta of 0.97. The stock has a 50 day simple moving average of $496.82 and a 200-day simple moving average of $548.19. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period last year, the business posted $5.15 EPS. Thermo Fisher Scientific's quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.83 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,800 shares of company stock valued at $2,963,544 in the last three months. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Barclays dropped their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. UBS Group reaffirmed a "neutral" rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Morgan Stanley restated an "overweight" rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $623.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.